Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide

Bibliography

• WHO DATABASE: WHO Media Centre. Fact Sheet (2002):138.
   Google Scholar
• JOY SV, RODGERS PT, SCATES AC: Incretin mimetics as emerging treatments for Type 2 diabetes. Ann. Pharmacother. (2005) 39:110-118.
   PubMed Web of Science ®Google Scholar
• POON T, NELSON P, SHEN L et al.: Exenatide improves glycemic control and reduces body weight in subjects with Type 2 diabetes: a dose ranging study. Diabetes Technol. Ther. (2005) 7(3):467-477.
   PubMedGoogle Scholar
• KOLTERMAN O, BUSE J, FINEMAN M et al.: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with Type 2 diabetes. J. Endocrinol. Metab. (2003) 88(7):3082-3089.
   PubMed Web of Science ®Google Scholar
• MEIER J, NAUCK M: Glucagon like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab. Res. Rev. (2005) 21:91-117.
   PubMed Web of Science ®Google Scholar
• NIELSEN L, YOUNG A, PARKES D: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of Type 2 diabetes. Regul. Peptides (2004) 117:77-88.
   PubMed Web of Science ®Google Scholar
• LIPSY R: The National Cholesterol Education Program Adult Treatment Panel III guidelines. J. Manag. Care Pharm. (2003) 9(Suppl. 1):2-5.
   PubMedGoogle Scholar
• UKPDS: Effect of the intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854-865.
   PubMed Web of Science ®Google Scholar
• Guías ALAD 2000 para el diagnóstico y manejo de la diabetes mellitas Tipo 2 con medicina basada en la evidencia. Revista ALAD, edición extraordinaria (2000) (Suppl. 1):3-22.
   Google Scholar
• MELTZER S, LEITER L, DANEMAN D et al.: Clinical practice guidelines for the management of Diabetes in Canada. Canada Med. Assoc. J. (1998) 159(Suppl. 8):S1-S29.
   PubMed Web of Science ®Google Scholar
• ELRICK H, STIMMLER, HLAD C et al.: Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. (1964) 24:1076-1082.
   PubMed Web of Science ®Google Scholar
• DRUCKER DJ: Enhancing incretin action for the treatment of Type 2 diabetes. Diabetes Care (2003) 26:2929-2940.
   PubMed Web of Science ®Google Scholar
• CHAIKOMIN R, DORAN S, JONES KL: Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am. J. Physiol. Endocrinol. Metab. (2005) 289(3):E504-E507.
   PubMed Web of Science ®Google Scholar
• ZANDER M, MADSBAD S, DEACON CF: The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with Type 2 diabetes. Diabetologia (2006) 49(2):369-374.
   PubMed Web of Science ®Google Scholar
• DEACON C, AHREN B, HOLST J: Inhibitors of dipeptydyl peptidase 4: a novel approach for the prevention and treatment of Type 2 diabetes mellitus? Expert Opin. Invest. Drugs (2004) 13(9):1091-1102.
   PubMed Web of Science ®Google Scholar
• LANKAS G, LEITING B, ROY R et al.: Dipeptidyl peptidase iv inhibition for the treatment of Type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes (2005) 54(10):2988-2994.
   PubMed Web of Science ®Google Scholar
• HUPE SODEMANN K, GÖKE R, GÖKE B: Endoproteolysis of glucagon like peptide (GLP)-1(7-36) amide by ectopeptidases in RINm5F cells. Peptides (1997) 18(5):625-632.
   PubMed Web of Science ®Google Scholar
• UKPDS: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes mellitus (UKPDS 33). Lancet (1998) 352(9131):837-853 [Erratum in: Lancet (1999) 354(9178):602].
   PubMed Web of Science ®Google Scholar
• UKPDS 16: UK prospective diabetes study 16. Overview of 6 years´ therapy of Type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes (1995) 44:1249-1258.
   PubMed Web of Science ®Google Scholar
• NAUCK M, HEIMESAAT M, BEHLE K et al.: Effects of glucagons like peptide-1 on conterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab. (2002) 87(3):1239-1246.
   PubMed Web of Science ®Google Scholar
• GERICH JE: Abnormal glucagon secretion in Type 2 diabetes mellitus: causes and consequences. Diabetes Mellitus: Pathophysiol. Ther. (1989):127-133.
   Google Scholar
• FLINT A, RABEN A, ASTRUP A et al.: Glucagon like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. (1998) 101:515-520.
   PubMed Web of Science ®Google Scholar
• LITTLE TJ, PILICHIEWICZ AN, RUSSO A et al.: Effects of intravenous GLP-1 on gastric emptying and intragastric distribution in healthy subjects – relationships with postprandial glycemic and insulinemic responses. J. Clin. Endocrinol. Metab. (2006) 91(5):1916-1923.
   PubMed Web of Science ®Google Scholar
• MEIER JJ, GALLWITZ B, SALMEN S et al.: Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. (2003) 88(6):2719-2725.
   PubMed Web of Science ®Google Scholar
• BLASÉ E, TAYLOR K, GAO HY et al.: Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J. Clin. Pharmacol. (2005) 45(5):570-577.
   PubMed Web of Science ®Google Scholar
• SCHICK R, ZIMMERMANN J, WALDE T et al.: Peptides that regulate food intake: glucagon like peptide 1 amide at lateral and medial hypothalamic sites to suppress feeding in rats. Am. J. Physiol. (2003) 234:R1427-R1435.
   Google Scholar
• NAUCK MA, HEIMESAAT MM, ORSKOV C: Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with Type 2 diabetes. J. Clin. Invest. (1993) 91(1):301-307.
   PubMed Web of Science ®Google Scholar
• TOFT-NIELSEN MB, DAMHOLT M, MADSBAD S: Determinants of the impaired secretion of Glucagon-like Peptide-1 in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2001) 86(8):3717-3723.
   Google Scholar
• AHREN B, LANDIN-OLSSON M, JANSSON P et al.: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes. J. Clin. Endocrinol. Metab. (2004) 89(5):2078-2084.
   PubMed Web of Science ®Google Scholar
• AHREN B, GOMIS R, STANDL E et al.: Twelve- and 52-weeks efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care (2004) 27(12):2874-2879.
   PubMed Web of Science ®Google Scholar
• GIANNOUKAKIS N: Exenatide Amylin/Eli Lilly. Curr. Opin. Investig. Drugs (2003) 4(4):459-465.
   PubMedGoogle Scholar
• EGAN J, MENEILLY G, ELAHI D: Effects of 1-mo bolus subcutaneous administration of exendin-4 in Type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. (2003) 284(6):E1072-E1079.
   PubMed Web of Science ®Google Scholar
• KEETING GM: Exenatide. Drugs (2005) 65(12):1681-1692.
   PubMed Web of Science ®Google Scholar
• KNUDSEN LB, NIELSEN PF, HUUSFELDT PO et al.: Potent derivatives of glucagons like 1 peptide with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. (2000) 43:1664-1669.
   PubMed Web of Science ®Google Scholar
• CALARA F, TAYLOR K, ZABALA E et al.: A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin. Ther. (2005) 27(2):210-215.
   PubMed Web of Science ®Google Scholar
• FINEMAN M, BICSAK T, SHEN L et al.: Effect of glycemic control of exenatide (synthetic exendin-4) additive to existing metformine and/or sulfonylurea treatment in patients with Type 2 diabetes. Diabetes Care (2003) 26(8):2370-2377.
   PubMed Web of Science ®Google Scholar
• HILES R, BAWDON, PETRELLA E: Ex vivo human transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Hum. Exp. Toxicol. (2003) 22(12):623-628.
   PubMed Web of Science ®Google Scholar
• AGERSO H, JENSEN LB, ELBROND B: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long acting GLP-1 derivative, in healthy men. Diabetologia (2002) 45:195-202.
   PubMed Web of Science ®Google Scholar
• ELBROND B, JAKOBSEN G, LARSEN S et al.: Pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN2211, a long acting glucagons like peptide 1 derivative, in healthy male subjects. Diabetes Care (2002) 25:1398-1404.
   PubMed Web of Science ®Google Scholar
• MAGER D, ABERNETHY D, EGAN J et al.: Exendin-4 pharmacodynamics: insights of the hyperglycemic clamp technique. J. Pharmacol. Exp. Ther. (2004) 311(2):830-835.
   PubMed Web of Science ®Google Scholar
• EGAN J, CLOCQUET A, ELAHI D: The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to Type 2 diabetes. J. Clin. Endocrinol. Metab. (2002) 87(3):1282-1290.
   PubMed Web of Science ®Google Scholar
• DEGN K, BROCK B, JUHL C et al.: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose dependent insulin secretion and counterregulation during hypoglycemia. Diabetes (2004) 53:2397-2403.
   PubMed Web of Science ®Google Scholar
• HARDER H, NIELSEN L, TU DT et al.: The effect of liraglutide, a long acting glucagon like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care (2004) 27(8):1915-1921.
   PubMed Web of Science ®Google Scholar
• DEGN KB, JUHL CB, STURIS J et al.: One weeek´s treatment with the long acting GLP 1 derivative, liraglutide (NN2211), markedly improves 24 hour glycemia, α and β cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes (2004) 53:1187-1194.
   PubMed Web of Science ®Google Scholar
• MOVASSAT J, BEATTIE G, LOPEZ A et al.: Exendin-4 up-regulates expression of PDX and hastens differentiation and maturation of human fetal pancreatic cells. J. Clin. Endocrinol. Metab. (2002) 87(10):4775-4781.
   PubMed Web of Science ®Google Scholar
• BREGENHOLT S, MOLDRUP A, BLUME N et al.: The long-acting glucagons like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. (2005) 330:577-584.
   PubMed Web of Science ®Google Scholar
• GEDULIN B, SMITH P, PRICKETT K et al.: Dose–response for glycemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia (2005) 48:1380-1385.
   PubMed Web of Science ®Google Scholar
• EDWARDS M, STANLEY S, DAVIS R et al.: Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. Endocrinol. Metab. (2001) 281:E155-E161.
   PubMed Web of Science ®Google Scholar
• DUPRE J, BEHME M, McDONALD T: Exendin-4 normalized postcibal glycemic excursions in Type 1 diabetes. J. Clin. Endocrinol. Metab. (2004) 89(7):3469-3473.
   PubMed Web of Science ®Google Scholar
• MADSBAD S, SCHMITZ O, RANSTAM J et al.: Improved glycemic control with no weight increase in patients with Type 2 diabetes after once-daily treatment with the long-acting glucagon like peptide 1analog liraglutide (NN2211). Diabetes Care (2004) 27(6):1335-1342.
   PubMed Web of Science ®Google Scholar
• BUSE J, HENRY R, HAN J et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureas treated patients with Type 2 diabetes. Diabetes Care (2004) 27:2628-2635.
   PubMed Web of Science ®Google Scholar
• GUTZWILLER JP, DREWE J, GÖKE B: Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus Type 2. Am. J. Physiol. (1999) 276:R1541-R1544.
   PubMed Web of Science ®Google Scholar
• FEINGLOS MN, SAAD MF, PI-SUNYERT FX: Effects of liraglutide (NN2211), a long acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med. (2005) 22:1016-1023.
   PubMed Web of Science ®Google Scholar
• ADA: Standards of medical care in diabetes. Diabetes Care (2004) 27(Suppl. 1):S15-S35.
   PubMedGoogle Scholar
• FINEMAN M, SHEN L, TAYLOR K et al.: Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose limiting side effects in subjects with Type 2 diabetes. Diabetes Metab. Res. Rev. (2004) 20:411-417.
   PubMed Web of Science ®Google Scholar
• IDF: A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet. Med. (1999) 16(9):716-730.
   PubMed Web of Science ®Google Scholar